ambrisentan   Click here for help

GtoPdb Ligand ID: 3951

Synonyms: Letairis®
Approved drug
ambrisentan is an approved drug (FDA (2007), EMA (2008))
Compound class: Synthetic organic
Comment: Ambrisentan is an endothelin receptor antagonist, with selectivity for the type A endothelin receptor (ETA).
Click here for help
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ambrisentan

2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 81.54
Molecular weight 378.16
XLogP 3.67
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES COC(C(C(=O)O)Oc1nc(C)cc(n1)C)(c1ccccc1)c1ccccc1
Isomeric SMILES COC([C@@H](C(=O)O)Oc1nc(C)cc(n1)C)(c1ccccc1)c1ccccc1
InChI InChI=1S/C22H22N2O4/c1-15-14-16(2)24-21(23-15)28-19(20(25)26)22(27-3,17-10-6-4-7-11-17)18-12-8-5-9-13-18/h4-14,19H,1-3H3,(H,25,26)/t19-/m1/s1
No information available.
Summary of Clinical Use Click here for help
Approved to treat pulmonary arterial hypertension (PAH).
Ambrisentan is being evaluated in Phase 3 clinical trial for the additional indication chronic thromboembolic pulmonary hypertension.

COVID-19: In response to the SARS-CoV-2 pandemic, clinical trials were initiated to address the potential of endothelin receptor antagonism as a treatment for endothelial cell damage and dysfunction in the blood vessels (in the lungs and other organs) that occurs during SARS-CoV-2 infection.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Ambrisentan is a selective endothelin receptor A (ETA) antagonist. Antagonism of endothelin binding to ETA decreases vasoconstriction in the smooth muscle of the lungs and reduces pulmonary blood pressure.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04393246 mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms Phase 2/Phase 3 Interventional Cambridge University Hospitals NHS Foundation Trust
NCT04771000 A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19 Phase 2 Interventional Noorik Biopharmaceuticals AG